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Erythropoiesis after withdrawal of enalapril in post-transplant eryth-
rocytosis. Enalapril effectively decreases hematocrits in patients with
postrenal transplant erythrocytosis (PTE). We studied the effect of
enalapril withdrawal on eiythropoiesis in 18 patients with PTE who had
been treated for 13 8 months. Hematocrit, reticulocyte count, plasma
erythropoietin, and plasma insulin-like growth factor I were measured
biweekly for six weeks. Red cell mass, plasma volume, transferrin satura-
tion, and plasma angiotensin II were measured at withdrawal and six
weeks later. Hematocrit increased by at least 0.04 in 13 patients ('respond-
ers') but changed by —0.08 to 0.01 in five patients ('nonresponders'). In
the responder subgroup, hematocrit increased from 0.43 0.05 to 0.51
0.05 (P < 0.001), red cell mass increased from 25.4 5.9 to 28.9 5.9
ml/kg body weight (P < 0.001), and transferrin saturation decreased from
41 16 to 27 9 percent (P < 0.01). Reticulocyte count increased two
weeks after withdrawal of enalapril. Plasma volume did not change
significantly. No measurement changed in the nonresponder subgroup.
Plasma levels of erythropoietin, total erythroid stimulating activity, insu-
lin-like growth factor I, and angiotensin II did not change significantly in
either subgroup. Enalaprilat did not inhibit erythropoiesis in cell culture.
Thus, erythropoiesis increased in 13 of 18 patients after stopping enalapril
and was independent of changes in circulating concentrations of several
erythropoietic factors, including erythropoietin. The pathogenesis of PTE
and mechanism underlying the beneficial effect of angiotensin converting
enzyme inhibition remain undetermined.
Following reports of angiotensin converting enzyme inhibitor-
induced anemia after renal transplantation [19—22], we began
treating erythrocytotic renal transplant patients with enalapril in
1990. We found that small doses of enalapril safely decreased
hematocrits in most patients within weeks [23]. Other transplant
centers have confirmed the efficacy of enalapril [24—30] or found
a similar response to other angiotensin converting enzyme inhib-
itors, including captopril [31—33], lisinopril [24, 28], and fosinoprilj28]. In a few patients at our center the hematocrit quickly
returned to pretreatment levels after enalapril was discontinued.
This observation led us to undertake a prospective study of
erythropoiesis after withdrawal of enalapril in erythrocytotic renal
transplant patients who had responded to the agent. We postu-
lated that clinical and hormonal changes might mimic those
originally leading to post-transplant erythrocytosis, and thus pro-
vide insight into its pathophysiology.
Methods
Patient selection
Erythrocytosis (an elevation in red cell mass with normal
plasma volume) develops in 5 to 17% of renal transplant recipi-
ents, generally within two years after engraftment [1—3]. Its
frequency may be higher in patients taking cyclosporine than in
patients taking azathioprine and prednisone [4, 5]. The cause of
post-transplant erythrocytosis is uncertain, but some evidence has
indicated a central role for increased renal production of eryth-
ropoietin, either in the renal allograft or native kidneys [6—9].
While the hematocrit may spontaneously decrease to normal on
occasion [10, 11], in many patients the hematocrit remains
elevated for years [12, 13]. Because of an increased risk for
thrombosis, many transplant centers strive to maintain the hemat-
ocrit less than 0.55 [13, 14]. Treatment regimens have included
serial phlebotomies, native nephrectomy [15, 16j, and oral theo-
phylline [17, 18]. None of these interventions has proven optimal.
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One hundred and twenty-six renal transplant patients at the
University of Alabama at Birmingham have been treated with
enalapril since 1990 for post-transplant erythrocytosis, defined as
an hematocrit equal to or higher than 0.52 on three consecutive
clinic visits. The hematocrit normalized in 124 patients. Eighteen
adult patients who had responded to enalapril volunteered to stop
the drug. The clinical characteristics of these subjects at entry into
the study are summarized in Table 1. No patient had clinical,
laboratory or radiographic evidence of hepatic dysfunction or
pulmonary disease. The cause of end-stage renal disease was
chronic glomerulonephritis in six patients, polycystic kidney dis-
ease in four patients, hypertension in two patients and type I
diabetes mellitus in one patient; the cause was unknown in five
patients. Fourteen patients were taking cyclosporine, azathio-
prine, and prednisone for immunosuppressive therapy, two pa-
tients were taking azathioprine and prednisone, and two patients
were taking cyclosporine and azathioprine. The doses of diuretic,
antihypertensive, and immunosuppressive medications were not
changed during the study. Sustained release nifedipine was used
to treat hypertension in the presence of diastolic pressure greater
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Table 1. Demographic and clinical features of 18 renal transplant
patients at the time of stopping enalapril treatment of erythrocytosis
Gender, men:women
Cause of end-stage renal disease
chronic glomerulonephritis
polycystic kidney disease
hypertension
diabetes mellitus, type 1
unknown
Nonsmokers
Diuretic therapy
Retained native kidneys
Source of allograft, cadaveric:living donor
Hematocrit before enalapril treatmenta
Interval between transplantation and
starting enalapril, monthsa
Enalapril dose, mg per daya
Duration of enalapril treatment, monthsa
a Data are mean Sn.
than 105 mm Hg. No patient was taking or started on an iron
supplement during the study.
The study was approved by the Institutional Review for Human
Use at the University of Alabama at Birmingham. Informed
consent was obtained from all patients before participation.
Study design
At inception of the study, patients were evaluated within 24
hours of the last dose of enalapril as outpatients in the General
Clinical Research Center. After reclining on a tilt-table for 15
minutes, patients were raised to an upright position for ten
minutes. Blood pressure was measured, and venous blood was
drawn for measurement of serum creatinine, hematocrit, hemo-
globin, red cell count, reticulocyte count, plasma erythropoietin,
plasma renin activity, insulin-like growth factor I, and plasma
angiotensin II. After venipuncture, red cell mass and plasma
volume were measured. Hematocrit, hemoglobin, and reticulocyte
count, and upright blood pressure were measured two and four
weeks later. Six weeks after withdrawal of enalapril, all measure-
ments obtained on the first day of the study were repeated.
Laboratoty tests
Hemoglobin concentration, hematocrit, and red cell count were
measured using a Sysmex NE-8000 (Toa Medical Electronics
Co., Ltd., Kobe, Japan). The reticulocyte count was measured
using a Sysmex R-1000 Instrument (Toa Medical Electronics
Co., Ltd.) and corrected to a hematocrit of 0.45, Serum creatinine,
iron concentration, and total iron binding capacity were measured
with use of a Technicon SMAC-Il computerized AutoAnalyzer
(Technicon, Tariytown, New York, USA). Red cell mass was
determined by 51chromium-labeled red cells and plasma volume
was measured by 125iodine-radioiodinated albumin. Oxygen satu-
ration of hemoglobin was measured at a fingertip with a pulse
oximeter. Plasma levels of biologically active erythropoietin were
determined in triplicate using a highly specific in vitro bioassay
[34] that is more sensitive than the commonly used immunoassays
[34, 35]. Its specificity for erythropoietin is equivalent to that of
immunoassays because an immobilized monoclonal antibody with
high affinity to erythropoietin [36] is used to absorb and concen-
trate the plasma erythropoietin before it is tested in the in vitro
assay. The in vitro bioassay is based on 3H-thymidine incorpora-
tion into a highly enriched population of erythroid progenitors,
that is, spleen cells from phenyihydrazine-treated mice [37] and
15:3 therefore measures biologically active erythropoietin. Previous
studies have established that levels obtained with this assay [34]
6 are very similar to those obtained with competitive radioimmu-
noassays [38] and enzyme-linked immunoabsorbent assays [38].
Plasma insulin-like growth factor I concentrations were measured
5 at Endocrine Sciences, (Calabasas Hills, California, USA) using
14 an immunoassay with an antiserum directed against a synthetic
segment of the insulin-like growth factor I sequence (IGF-I 57-70)
12'6 [39]. Plasma renin activity and plasma angiotensin II levels were
0.55 o.oz measured using modifications of previously described methods
34 23 [40]. Aside from erythropoietin, angiotensin II, and insulin-like
growth factor I, other circulating factors may influence erythro-5.5 3.6 poiesis; some insight can be obtained by measuring the total
—
erythroid stimulating activity of plasma. To measure the total
erythroid stimulating activity within the plasma of these patients,
unfractionated plasma at a final concentration of 1% was tested in
the presence of 25 mU/mi of erythropoietin, using the same in
vitro assay [37] without the anti-erythropoietin monoclonal anti-
body step [34]. Results were expressed as mU/mi erythropoietin.
Thus, a value greater than 25 mU/ml would signify stimulation of
erythropoiesis greater than that observed when erythropoietin 25
mU/ml was used in the assay. The direct effect of enalapril on
erythropoiesis was determined by dissolving enalaprilat (Merck,
Rahway, New Jersey, USA) in DMEM and testing various
concentrations in the presence and absence of 25 mU/mi of
erythropoietin in the same assay [37].
Statistical analysis
Mean arterial blood pressure was calculated as the diastolic
blood pressure plus one third of the pulse pressure.
Paired t-tests were used to compare timed changes between the
start and end of the study. Analysis of variance was used to
compare differences in serially collected specimens. Unpaired
t-tests were used to compare intergroup differences. Tukey's
studentized range test was used to compare pair combinations of
time points of serially collected specimens [41]. Linear regression
was used to assess the rate of change in serially collected
specimens. Regression analysis was used to assess relationships
between changes in hematologic and biochemical measurements.
A P value of less than 0.05 was considered to indicate statistical
significance. Results were expressed as mean Sn.
Results
Clinical
The mean arterial blood pressure was 101 11 mm Hg at the
start of the study and did not change six weeks later (103 10mm
Hg) (Table 2). One patient required treatment with sustained-
release nifedipine for hypertension. No patient developed venous
thrombosis after stopping enalapril.
Laboratoiy measurements
The serum creatinine concentration was 1.6 0.5 mg per dl at
the beginning of the study and did not change following with-
drawal of enalapril. The peripheral oxygen saturation was normal
at the start of the study and six weeks later (98 1% and 97
1%, respectively).
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Table 2. Laboratory measurements in 18 renal transplant patients after withdrawal of enalapril treatment of eiythrocytosis
N
Weeks after withdrawal
0 2 4 6
Hematocrit
All 18 0.44 0.04 0.46 0,05b 0.47 0.04" 0.49 0.05c
Responders 13 0.43 0.05 0.46 0.05a 0.48 0.05a 0.51 0•05b
Nonresponders 5 0.46 0.04 0.47 0.04 0.45 0.03 0.45 0.04
Corrected reticulocyte, %
All 18 1.6 0.4 2.3 Li" 2.2 1.0" 1.9 0.9
Responders 13 1.6 0.6 2.6 1.la 2.6 1.1 2.1 0.9
Nonresponders 5 1.3 0.4 1.6 Ø,5 1.5 0.5 1.4 0.3
Red cell mass, mi/kg body wt
All 18 25.3 5.9 28.3 57a
Responders 13 25.4 5.9 28.9 5•9C
Nonresponders 5 24.6 1.2 25.4 2.8
Plasma volume, mi/kg body wt
All 18 39.9 4.5 39.0 4.1
Responders 13 40.0 4.3 38.6 3.8
Nonresponders 5 39.5 5.6 39.9 5.2
Transferrin saturation, %
All 18 39±15 27±8a
Responders 13 41 16 27 9b
Nonresponders 5 31 8 26 8
Erythropoietin, mU/mi
All 18 28 28 36 32 34 26 36 26
Responders 13 33 30 42 35 35 22 42 26
Nonresponders 5 15 14 20 19 30 35 19 17
Angiotensin II, pg/mi
All 14 35±29 47±44
Responders 10 42 32 54 48
Nonresponders 4 19 13 22 16
Insulin-like growth factor I, ng/mi
All 18 261 78 255 79 251 83 259 75
Responders 13 258 87 253 90 243 89 260 85
Nonresponders 5 272 59 261 50 272 70 259 49
Plasma renin activity, ng/mi/h
All 18 2.0 1.6 0.4 o.8
Responders 13 1.8 1.2 0.3 0.2c
Nonresponders 5 2.6 2.3 0.8 1.5
Total erythroid stimulating
activity, mU/mi
All 18 13.0 6.3 12.1 6.8
Responders 13 11.5 5.8 10.6 5.8
Nonresponders 5 16.6 6.8 16.2 4.8
Data are mean SD.
Data compared with values at week 0: a P < 0.05, bp < 0.01, c P < 0.001
In the entire study group (N = 18), mean hematocrit progres-
sively increased from 0.44 0.04 to 0.49 0.05 six weeks after
stopping enalapril (P < 0.001; Table 2, Fig. 1). At the end of the
study, the group was divided into two subgroups based upon
change in hematocrit. Thirteen patients in whom the increase was
0.04 or greater were labeled as 'responders.' Five patients, in
whom the change in hematocrit ranged from —0.08 to 0.01, were
labeled 'nonresponders'. These subgroups were similar demo-
graphically (source of allograft, cause of end-stage renal disease,
and race). Mean hematocrit in the responders increased from 0.43
0.05 to 0,51 0.04 (P < 0.01; Table 2). In six patients the
increase was at least 0.07. Reticulocyte count was significantly
higher than baseline in the responder subgroup two weeks after
discontinuing enalapril, compared with a stable reticulocyte count
in the nonresponders (Table 2). In the responders, red cell mass
increased from 25.4 5.9 ml per kg body weight at the start of the
study to 28.9 5.9 ml per kg (P < 0.001) six weeks later, but did
not significantly change in the nonresponders (Table 2). In
contrast, plasma volume was normal at the start of the study in
both subgroups of patients and did not change significantly (Table
2). Transferrin saturation in the responder subgroup decreased
from 41 16% at the start of the study to 27 9% (P < 0.01) six
weeks later, and did not change significantly in the nonresponders
(31 8% versus 26 8%).
The erythropoietic response did not correlate with duration or
dose of enalapril treatment before entry into the study. The 0.07
0.04 increase in hematocrit during the study in the five patients
treated for the longest intervals (23 4 months, range 18 to 28)
did not differ from the 0.06 0.05 increase in the five patients
treated for the shortest intervals (5 2 months, range 2 to 6). The
increase in hematocrit did not differ between recipients of cadav-
eric allografts and recipients of living-related donor allografts or
between patients taking a diuretic medication and patients taking
none. Change in hematocrit did not correlate with age of the
donors of the allografts.
At the start of the study the plasma erythropoietin level in the
Fig. 1. The hematocrits of 18 renal transplant
patients after stopping enalapril treatment for
eiythrocytosis. The mean hematocrit
progressively increased after stopping enalapril,
increasing from 0.44 0.04 at baseline to 0.49
0.05 six weeks later (P < 0.001). The
hematocrit was at least 0.04 higher than
6 baseline in 13 'responder' patients after six
weeks (solid lines). In five 'nonresponder'
patients the change in hematocrit ranged from
—0.08 to 0.01 (broken lines),
Fig. 2. The plasma levels of biologically active
e'ythropoietin in 18 renal transplant patients after
stopping enalapril treatment for etythrocytosis.
The mean plasma erythropoietin level did not
significantly change after stopping enalapril. In
the 'responder' patients (solid lines) the plasma
erythropoietin showed no significant change
after withdrawal: 33 30 mU/mi at baseline
versus 42 35 mU/ml at two weeks (P = 0.12),
35 22 mU/mI at four weeks (P = 0.72), and
42 26 mU/mI at six weeks (P = 0.46). The
'nonresponder' patients (broken lines) also
showed no significant change: 15 14 mU/mi
6 at baseline versus 20 19 mU/mi at two weeks(P = 0.19), 30 35 mU/mi at four weeks (P =
0.22), and 19 17 mU/mI at six weeks (P =
0.46).
18 patients was 28 28 mU per ml (Table 2), a value in the
normal range for a mean hematocrit of 0.43 [321. The plasma
erythropoietin level did not change after stopping enalapril: 38 t
31 mU/mi, 34 26 mU/ml, and 36 t 26 mU/ml at two, four, and
six weeks, respectively (Table 2, Fig. 2). In six patients the plasma
erythropoietin level one week after withdrawal did not signifi-
cantly differ from baseline (12 10 mU/ml vs. 7 6 mU/ml, P =
0.42). The 13 responders showed no significant change in plasma
erythropoietin level after withdrawal: 33 30 mU/mi at baseline
versus 42 35 mU/ml at two weeks (P = 0.12), 35 22 mU/ml
at four weeks (P = 0.72), and 42 26 mU/ml at six weeks (P =
0.46) (Table 2). While the plasma erythropoietin levels tended to
be lower in the nonresponders, the difference between subgroups
neared statistical significance only at six weeks after withdrawal of
enalapril (P = 0.08), but not at all other times (P > 0.20).
Nonetheless, in one patient whose hematocrit increased by 0.06
the plasma erythropoietin level remained just above the lower
limit of detection throughout the six weeks. Neither change in
hematocrit nor change in reticulocyte count in the responder
subgroup correlated with the plasma erythropoietin level mea-
sured contemporaneously or two weeks earlier.
For all 18 patients, the plasma renin activity decreased from 2.0
1.6 ng/ml per hour at the start of the study to 0.4 0.8 ng/ml
per hour six weeks later. The decrease was statistically significant
in the responder subgroup, but not in the nonresponder subgroup
(Table 2). The plasma angiotensin II level did not change
significantly during this interval in the responder subgroup (P =
0.27) or in the nonresponder subgroup (P = 0.53; Table 2). The
differences in the plasma angiotensin II levels between subgroups
was not significant at withdrawal of enalapril (P = 0.20) or six
weeks later (P = 0.24). For the responder subgroup, the plasma
angiotensin II level correlated with the plasma erythropoietin
level (P = 0.02) and the reticulocyte count (P = 0.02) at withdrawal
of enalapril, but not six weeks later. The plasma renin activity did
not correlate with plasma erythropoietin level or reticulocyte
count at either time point. Plasma concentrations of insulin-like
growth factor 1 were normal at the start of the study and did not
significantly change after withdrawal of enalapril (Table 2).
0 2 4
Time, weeks after withdrawal of enalapril
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At withdrawal from enalapril the total erythroid stimulating
activity in the 18 patients was lower than that of normal volun-
teers, 13.5 6.3 mU/ml versus 25.3 4.4 mU/ml. Total erythroid
stimulating activity did not change in the six weeks in all patients
(13.5 6.3 mU/ml vs. 12.1 6.8 mU/ml) or in the responder
subgroup (11.5 5.8 mU!ml vs. 10.6 5.8 mU/ml; Table 2). Only
two patients had normal total erythroid stimulating activity at the
start of the study. Only one patient had a normal value six weeks
after withdrawal of enalapril and only one patient showed an
increase greater than 5 mU/ml during the study.
Because the erythropoietic response after withdrawal of enala-
pril was not explained by an increase in circulating levels of
erythropoietic stimulating factors, we evaluated the direct effect of
enalaprilat on erythropoiesis. No inhibitory or stimulating effect
was observed when concentrations of enalaprilat from 0.001 to 0.5
mg/mI were tested, in the presence and absence of 25 mU/ml of
erythropoietin (data not shown).
At the end of the study, treatment with enalapril was restarted
at its previous dosage in eight responder patients. Four weeks
later the hematocrit decreased significantly from 0.53 0.03 to
0.49 0.02 (P < 0.05). Additional observation of the nonre-
sponder patients showed stable hematocrits three months after
stopping enalapril. Thus, erythrocytosis did not recur in these five
patients.
Discussion
Enalapril has been shown to safely reduce the hematocrit in
renal transplant patients with erythrocytosis [23—30]. The current
study was designed to determine whether erythrocytosis would
recur after discontinuation of enalapril, and to test whether
recurrence would be explained by changes in plasma levels of
erythropoietic factors. The hematocrit promptly increased after
withdrawal of enalapril in 13 (72%) of 18 patients. This increase
represented true erythropoiesis, as confirmed by increases in red
cell mass and reticulocyte count, stable plasma volume, and a
decrease in transferrin saturation. We found erythropoiesis to
occur independently of changes in circulating levels of several
known erythropoietic factors: erythropoietin, angiotensin II, and
insulin-like growth factor I. Furthermore, the increased produc-
tion of red blood cells was apparently not due to withdrawal of a
direct inhibitory effect of the active metabolite of enalapril,
enalaprilat, on erythropoietic precursors in the marrow. These
data indicate that the pathogenesis of posttransplant erythrocyto-
sis and the mechanism underlying its response to angiotensin
converting enzyme inhibition are more complex than simple
alteration of plasma erythropoietin levels, but remain uncertain.
The suppressive action of enalapril on erythropoiesis is not
unique to this angiotensin converting enzyme inhibitor or the
post-transplant setting. Other angiotensin converting enzyme
inhibitors, including captopril [21, 3 1—33], lisinopril [28], and
fosinopril [28], have been shown to decrease hematocrits in
erythrocytotic renal transplant patients. Angiotensin converting
enzyme inhibitors may also slow normal erythropoiesis after renal
transplantation. In a controlled study examining the effects of
angiotensin converting enzyme inhibitors and calcium channel
blockers on the function of renal allografts, patients treated with
lisinopril had lower hematocrits one year after transplantation
than patients treated with nifedipine [42]. Alternatively, angioten-
sin converting enzyme inhibitor-associated anemia has developed
in nontransplant patients, including normal volunteers [19], hy-
pertensive patients with normal function of native kidneys [19],
patients with moderate renal insufficiency [43, 44], and patients on
maintenance hemodialysis [45]. Collectively, these findings indi-
cate that correction of post-transplant erythrocytosis is due to an
effect shared by this class of agents rather than one unique to a
single thug.
Neither the cause of posttransplant erythrocytosis nor the basis
for the response to angiotensin converting enzyme inhibition has
yet been defined. Other investigators have postulated an impor-
tant role for erythropoietin after showing either high circulating
erythropoietin levels in patients with erythrocytosis [8, 9, 25,46] or
a correlation between decreases in hematocrit and erythropoietin
levels with enalapril treatment [25, 29]. These findings and the
observation that erythropoietin levels rebounded to normal in
healthy subjects two weeks after stopping enalapril [47] led us to
expect that erythropoietin levels would increase after discontinu-
ing enalapril. Such an effect might be anticipated for two reasons.
First, stopping an angiotensin converting enzyme inhibitor would
be expected to increase plasma angiotensin II levels. Angiotensin
II has been shown to stimulate erythropoietin secretion in exper-
imental animals, either directly or indirectly by increasing renin
substrate [48, 49]. Second, stopping enalapril in patients taking
cyclosporine may decrease renal perfusion, either of the allograft
or native kidneys, due to loss of angiotensin converting enzyme
inhibitor-induced renal vasodilation. Decreased renal perfusion
would decrease delivery of oxygen to a sensor currently postulated
to be located near the proximal tubules, thereby augmenting the
stimulus for renal production of erythropoietin [50].
In contrast to our expectations, the increased erythropoiesis
appeared to be independent of changes in circulating levels of
erythropoietin. Plasma erythropoietin levels after withdrawal of
enalapril did not change significantly, either in the total group of
patients or in the subgroup of 13 patients showing an erythropoi-
etic response. Furthermore, neither reticulocyte response nor
magnitude of rise in hematocrit correlated with plasma erythro-
poietin levels. It is possible that we missed an early rise in plasma
erythropoietin, but there was no evidence of such a change in the
six patients in whom levels were measured at one week. We have
previously shown that enalapril normalized hematocrits in eryth-
rocytotic renal transplant patients with undetectable circulating
erythropoietin [23]. In any event, the failure of plasma erythro-
poietin levels to decrease with progressive increase in hematocrit
indicates that the normal feedback loop regulating erythropoietin
production was not functioning appropriately.
Post-transplant erythrocytosis may not depend upon circulating
eiythropoietin. After the hematocrit increases to 0.32 following
transplantation, erythropoietin levels do not correlate with hemat-
ocrit and are often normal [51, 52]. One study found no evidence
of an increased erythropoietin effect on erythroid precursors in
the marrow of transplant patients with erythrocytosis [5]. While
the number of colony forming units-erythroid and burst forming
units-erythroid were increased compared with healthy controls,
the ratio of the two precursors was normal. The ratio should be
elevated if erythropoietin was the cause of the increased erythro-
poiesis. Alternatively, other investigators have shown spontaneous
growth of erythroid precursors in cultures of marrow or stem cells
from peripheral blood, consistent with an increased sensitivity to
small amounts of erythropoietin [53].
Our findings indicate that increased erythropoiesis after with-
drawal of enalapril was also independent of circulating levels of
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other erythropoietic factors. We measured circulating levels of
insulin-like growth factor I because this hormone has stimulatory
activity for erythropoietic precursor cells that is independent of
erythropoietin [54, 55]. However, erythropoiesis in the present
study increased without changes in the plasma levels of insulin-
like growth factor I. Nor did circulating angiotensin II appear to
mediate the erythropoietic response. We had anticipated that
plasma angiotensin II levels would increase after stopping the
angiotensin converting enzyme inhibitor, and cannot explain the
stable levels in the setting of the expected decrease in plasma
renin activity. The unaltered levels of these two hormones agree
with the lack of change in total erythroid stimulating activity, a
measure of the net balance of circulating biologically active
stimulatory and inhibitory influences on erythropoiesis. For sim-
ilar reasons, although we did not specifically measure renin
substrate, the lack of change in total erythroid stimulating activity
is evidence against a causative role of this hormone in the
erythropoiesis.
Enalapril treatment of patients with posttransplant erythrocy-
tosis may decrease erythropoiesis by a local effect in the marrow.
However, enalapril does not appear to exert a primary inhibitory
effect because addition of the active metabolite, enalaprilat, to
erythropoietic progenitors in cell culture did not decrease red cell
production. On the other hand, we could not ascertain whether
enalapril suppressed erythropoiesis secondarily by altering the
effects of local factors on erythropoietic cells. Erythroid precur-
sors in human marrow have receptors for insulin-like growth
factor I [56]. In contrast, while a localized renin-angiotensin
system has been defined in some organs [57], we are not aware
that a tissue-specific system has been identified in the marrow.
Contrary to the widespread opinion that post-transplant eryth-
rocytosis is self-limited [4, 7], most of the patients in this study
(72%) showed increased erythropoiesis after stopping enalapril.
In these patients, erythrocytosis did not spontaneously resolve or
pharmacologically remit during treatment with enalapril. The
basis for a lack of erythropoietic response in five patients was
uncertain. They were demographically indistinguishable from the
responders. Before and after stopping enalapril none of the five
patients was iron deficient or showed clinical evidence of deteri-
oration of allograft function. After withdrawal of enalapril, the
circulating levels of erythropoietin, angiotensin II, and insulin-like
growth factor I did not differ significantly from the levels in
patients exhibiting an erythropoietic response. None of the five
patients has shown a delayed response: three months after
stopping enalapril their hematocrits have remained stable; their
erythrocytosis appears to have resolved.
We conclude that erythropoiesis will quickly increase in most
renal allograft patients with post-transplant eiythrocytosis after
withdrawal of enalapril via a pathogenetic mechanism that is more
complex than increased circulating levels of erythropoietin. Al-
though reinstitution of treatment may be effective, prolonged
enalapril therapy is required for these patients to maintain
hematocrits at desired levels.
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